DGAP-News: Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of Immune Evasive Cells

DGAP-News: Kadimastem Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells 08.06.2022 / 13:00 The issuer is solely responsible for the content of this announcement. If the feasibility study is successful, it would be a s...

Related Keywords

Israel ,United States ,Tel Aviv ,Asaf Shiloni ,Mahendra Rao ,Kadimastem Isletrx ,Kadimastem Ltd ,Weizmann Institute Of Science ,Distribution Services ,Therapeutics Inc ,News Service ,Tel Aviv Stock Exchange ,Must Have Communications ,Implant Therapeutics ,Evaluation Agreement Towards ,Potential Licensing ,Implant Therapeutic ,Human Embryonic Stem Cells ,Professor Michel Revel ,Professor Emeritus ,Molecular Genetics ,Weizmann Institute ,Professor Revel ,Israel Prize ,Looking Statement ,Securities Law ,Corporate News ,Regulatory Announcements ,Dgap News ,Kadimastem ,Implant ,Herapeutics , ,Nc ,Evaluation ,Agreement ,Cowards ,Potential ,Icensing ,Nvasive ,Cells ,The ,